Key result
Nonagenarian patients undergoing TAVI had higher 30-day all-cause mortality compared to patients <90 years, though 1-year mortality was similar.
Why the study?
Does TAVI result in different mortality outcomes in nonagenarian patients compared to younger patients with symptomatic severe aortic stenosis?
Cohort (n=819)
Yes
Does TAVI result in different mortality outcomes in nonagenarian patients compared to younger patients with symptomatic severe aortic stenosis?
TAVI in nonagenarians is associated with higher 30-day and 2-year mortality compared to younger patients, though 1-year mortality rates appear similar.
Answers are grounded in this paper and cite their sources.
Nonagenarians face higher 30-day TAVI mortality risk; this cohort study leaves open optimal age-based selection criteria.
Background: Transcatheter aortic valve implantation (TAVI) has been established as a standard treatment in inoperable and high-risk elderly patients with severe aortic stenosis. There is a debate about clinical utility of TAVI in some very high-risk subgroups of patients, including those >90 years old. However, there is few data assessing the safety and the efficacy of TAVI in patients older than 90 years. We aimed to assess the early and long-term clinical outcomes in nonagenarian patients undergoing TAVI. Methods: Between January 2008 and February 2015, patients with symptomatic severe aortic stenosis underwent and were enrolled in the Brazilian multicenter registry. Among a total of 819 patients, 735 were <90 years and 84 (10.2%) were nonagenarian. Kaplan-Meier estimates of all-cause mortality is shown in Figure. Results: Nonagenarian patients were 12 years older than pts <90 years (92.4 years vs. 80.1 years; p<0.001). Compared with pts <90 years, nonagenarian patients had higher STS risk score (13.19% vs. 9.87%; p<0.001), lower body mass index (24.61±3.87 vs. 26.49±4.78 kg/m2; p=0.001). At 30 days the rate of all-cause mortality was higher in nonagenarian group (15.6% vs. 8.4%; p=0.04) with similar rates of death at 1-year (20.9% vs. 21.8%). After 2-year of follow-up there was also a higher event rate in nonagenarian patients.
No takes yet. Share an insight, caveat, or question.
Helber et al. (2017) conducted a cohort in symptomatic severe aortic stenosis (n=819). Age ≥90 years (nonagenarian) vs. Age <90 years was evaluated on 30-day all-cause mortality (p=0.04). Nonagenarian patients undergoing TAVI had higher 30-day all-cause mortality compared to patients <90 years, though 1-year mortality was similar.
Synapse has enriched 10 related papers. Consider them for comparative context: